HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Anti-Aging Supplement Moves Step Closer To EU Launch With EFSA Approval

Executive Summary

ChromaDex' dietary supplement Niagen, marketed to help US consumers "age better", has taken a step closer to EU launch with a positive opinion by the European Food Safety Authority. 

You may also be interested in...



Could ChromaDex’ Tru Niagen Block Coronavirus Infection?

In vitro data shows potential for Chromadex' Tru Niagen dietary supplement to block coronavirus infection. Chromadex' CEO Rob Fried tells HBW Insight about the company's background and Tru Niagen's recent UK launch. 

ChromaDex Business Blooms After Pulling Niagen Claims Under NAD Review

Since Council of Better Business Bureaus investigators in May 2018 asked about claims for Tru Niagen, ChromaDex pulled the ads while reaching milestones in product distribution and ingredient licensing.

Nestlé Developing Microbiome-Based Supplements with Dutch Partner

Nestlé Health Science is putting its financial weight behind the 

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT142464

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel